Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer
Epithelial Ovarian Cancer

Interventions: Drug: Quisinostat
Drug: Paclitaxel
Drug: Gemcitabine
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2016-04-05

Last Posted Date: 2016-05-03

Lead Sponsor: NewVac LLC

Target Recruit Count: 51

Registration Number: NCT02728492

Locations: 🇷🇺
BioEq LLC, Saint-Petersburg, Russian Federation
🇷🇺
Russian Oncological Research Center n.a. N. N. Blokhin RAMS, Moscow, Russian Federation
🇷🇺
State Healthcare Institution of Yaroslavl region "Regional Clinical oncology hospital", Yaroslavl, Russian Federation

and more 3 locations

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Phase 2

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Pemetrexed
Drug: Cisplatin

First Posted Date: 2016-04-01

Last Posted Date: 2020-02-12

Lead Sponsor: Guangdong Association of Clinical Trials

Target Recruit Count: 150

Registration Number: NCT02725918

Locations: 🇨🇳
Guangdong Lung cancer institute, Guangzhou, Guangdong, China

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Phase 2

Terminated

Conditions: Gastric Cancer
Gastroesophageal Junction Cancer

Interventions: Drug: Ramucirumab
Drug: Trastuzumab
Drug: Capecitabine
Drug: Cisplatin

First Posted Date: 2016-04-01

Last Posted Date: 2020-01-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 7

Registration Number: NCT02726399

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States

and more 3 locations

Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder

Phase 1

Withdrawn

Conditions: Muscle-invasive Transitional Cell Carcinoma of the Bladder

First Posted Date: 2016-03-31

Last Posted Date: 2017-03-07

Lead Sponsor: Oncolytics Biotech

Registration Number: NCT02723838

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Phase 2

Active, not recruiting

Conditions: Medulloblastoma

Interventions: Drug: Cisplatin
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Lomustine
Procedure: Magnetic Resonance Imaging
Radiation: Radiation Therapy
Drug: Vincristine
Drug: Vincristine Sulfate

First Posted Date: 2016-03-31

Last Posted Date: 2024-10-26

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 45

Registration Number: NCT02724579

Locations: 🇺🇸
Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States
🇺🇸
Tufts Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 194 locations

A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Atezolizumab
Drug: 5-FU
Drug: Bevacizumab
Drug: Gemcitabine
Drug: Nab-Paclitaxel
Drug: Leucovorin
Drug: Oxaliplatin
Drug: Cisplatin
Drug: Capecitabine

First Posted Date: 2016-03-22

Last Posted Date: 2021-07-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 243

Registration Number: NCT02715531

Locations: 🇺🇸
Stanford Cancer Institute; Hematology, Palo Alto, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 27 locations

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2

Active, not recruiting

Conditions: Biliary Tract Cancer
Metastatic Cancer
Advanced Cancer

Interventions: Drug: Cisplatin
Drug: Ramucirumab
Drug: Merestinib
Drug: Placebo IV
Drug: Placebo Oral
Drug: Gemcitabine

First Posted Date: 2016-03-17

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 309

Registration Number: NCT02711553

Locations: 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
UCSF Medical Center at Mission Bay, San Francisco, California, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 76 locations

Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)

Phase 2

Active, not recruiting

Conditions: Urothelial Carcinoma of the Bladder

Interventions: Drug: Methotrexate
Drug: Vinblastine
Drug: Doxorubicin
Drug: Cisplatin
Radiation: Intensity modulated radiation therapy (IMRT)
Procedure: Transurethral Resection of Bladder tumor
Drug: 5-FU
Drug: Mitomycin C

First Posted Date: 2016-03-17

Last Posted Date: 2024-12-24

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 78

Registration Number: NCT02710734

Locations: 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
Sidney kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States

and more 1 locations

Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Vinorelbine
Drug: Cisplatin
Radiation: Radiotherapy

First Posted Date: 2016-03-16

Last Posted Date: 2024-01-11

Lead Sponsor: Spanish Lung Cancer Group

Target Recruit Count: 68

Registration Number: NCT02709720

Locations: 🇪🇸
Hospital Lluís Alcanyís, Xàtiva, Valencia, Spain
🇪🇸
Hospital Universitario Lucus Augusti, Lugo, Spain
🇪🇸
H. Son Llàtzer, Palma de Mallorca, Spain

and more 15 locations

Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: Cisplatin
Radiation: External Beam Radiation Therapy
Radiation: Internal Radiation Therapy
Drug: nimotuzumab

First Posted Date: 2016-03-10

Last Posted Date: 2016-03-10

Lead Sponsor: Air Force Military Medical University, China

Target Recruit Count: 60

Registration Number: NCT02705612

Locations: 🇨🇳
Department of Radiation Oncology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy